Document Detail

Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
MedLine Citation:
PMID:  12641499     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The eradication of Helicobacter pylori decreases the antisecretory activity of omeprazole and lansoprazole. Rabeprazole is a potent proton pump inhibitor that may not be affected as greatly by H. pylori status.
AIM: To compare the effect of H. pylori eradication on intragastric acidity and plasma gastrin during dosing with lansoprazole, omeprazole, rabeprazole and placebo.
METHODS: Twenty-four healthy H. pylori-infected volunteers were studied on day 7 of dosing with placebo, lansoprazole 30 mg, omeprazole 20 mg and rabeprazole 20 mg, before and at least 5 weeks after H. pylori eradication. On each occasion, the 24-h intragastric acidity was measured by gastric aspiration. Plasma gastrin concentrations were measured hourly from 08.00 to 13.00 h.
RESULTS: Sixteen subjects completed the study. For all three drugs and placebo, H. pylori eradication increased intragastric acidity, particularly nocturnal acidity, and decreased plasma gastrin. There were no differences between the three drugs with respect to 24-h acidity, percentage of time pH > 4 or 5-h plasma gastrin, either before or after H. pylori eradication. Before eradication, the percentage nocturnal time at pH > 3 was significantly greater during rabeprazole than during lanso-prazole dosing.
CONCLUSIONS: The increase in intragastric acidity seen after H. pylori eradication during dosing with proton pump inhibitors is a drug-class effect, particularly affecting nocturnal acid control. This is related to increased spontaneous intragastric acidity after H. pylori eradication.
M P Williams; B Usselmann; A Chilton; J Sercombe; C U Nwokolo; R E Pounder
Related Documents :
3344909 - A prospective, randomized study comparing highly selective vagotomy and extended highly...
680489 - Evidence for a defective inhibition of pentagastrin-stimulated gastric acid secretion b...
983859 - Gastric secretory and motor inhibition induced by certain methyl analogues of prostagla...
7614109 - Local acid production and helicobacter pylori: a unifying hypothesis of gastroduodenal ...
2298369 - Gastric acid hypersecretion in refractory gastroesophageal reflux disease.
2924079 - Intragastric capsaicin enhances rat gastric acid elimination and mucosal blood flow by ...
16349849 - Microbial hydrocarbon co-oxidation. iii. isolation and characterization of an alpha, al...
2920379 - Acidogenesis by oral streptococci at different ph values.
3549019 - New chemical trends in ganglioside research.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  17     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-03-18     Completed Date:  2003-06-23     Revised Date:  2013-04-16    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  775-83     Citation Subset:  IM    
Centre for Gastroenterology, Royal Free and University College Medical School, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Ulcer Agents / therapeutic use*
Benzimidazoles / therapeutic use*
Breath Tests
Cross-Over Studies
Gastric Acid
Gastrins / blood
Helicobacter Infections / blood,  drug therapy*
Helicobacter pylori*
Hydrogen-Ion Concentration
Omeprazole / analogs & derivatives,  therapeutic use*
Urea / analysis
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Benzimidazoles; 0/Gastrins; 103577-45-3/lansoprazole; 32828355LL/rabeprazole; 57-13-6/Urea; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previous...
Next Document:  Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflu...